E2Fs function as transcription factors, with E2F1-3 as activators and E2F4-8 as repressors[@R3]--[@R8]. Although it is a maxim of mammalian cell cycle regulation that the E2F1-3 activator subclass is required for cell proliferation, the evidence for this is based almost exclusively on *in vitro* studies using cells derived from murine and human tissues or on the *in vivo* analysis of *Rb* mutant mice[@R1], [@R2]. Other experiments, however, suggest that these E2Fs can also function as repressors in complex with Rb[@R9]--[@R11], yet the relative contribution of activation version repression and the physiological contexts in which these contrary E2F functions are employed remain unclear.

To explore the functions of the E2F activator subclass, we derived *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/−^ ES cells ([Supplementary Fig. 1a, 1b](#SD1){ref-type="supplementary-material"}) and compared the consequences of inactivating the conditional *E2f3^LoxP^* allele in these cells versus in *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* MEFs. The expression of *E2f1*, *E2f2* and *E2f3* in wild type ES cells was generally higher than in MEFs and the loading of E2F3 protein on classic E2F target promoters was comparable between the two proliferating cell types ([Supplementary Fig. 2a-c](#SD1){ref-type="supplementary-material"}). Consistent with previous observations, the ablation of *E2f1-3* in MEFs with standard *cre*-expressing vectors led to the induction of p53 activity, the loading of E2F4-p130 repressor complexes on E2F target promoters and a marked decrease in E2F target expression ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 3a--c](#SD1){ref-type="supplementary-material"})[@R5]--[@R7]. Consequently, triply deficient MEFs underwent a complete cell cycle arrest ([Fig. 1b](#F1){ref-type="fig"})[@R5]--[@R7]. In contrast, *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^Δ^*^/−^(*TKO*) ES cells failed to activate p53 or form E2F4/p130 repressive complexes, and as a result, E2F target expression was unaffected and cells proliferated equally well as *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/−^ (*DKO*) control cells ([Supplementary Fig. 3a-c](#SD1){ref-type="supplementary-material"}).

We then evaluated whether triply-deficient ES cells could proliferate *in vivo*. Subcutaneous injection of *TKO* ES cells into athymic nude mice yielded efficient teratoma formation, producing mesoderm, endoderm, and ectoderm at a rate similar to *DKO* ES lines ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Fig. 4a, 4b](#SD1){ref-type="supplementary-material"}). Moreover, from *E2f1*^+/−^;*E2f2*^−/−^;*E2f3*^+/−^ intercrosses we recovered the expected number of live *TKO* embryos as late as E9.5, but none were recovered past E11.5 ([Fig. 1d](#F1){ref-type="fig"}, and data not shown). The live E9.5 *TKO* embryos appeared morphologically normal by gross and histological examination ([Fig. 1e](#F1){ref-type="fig"} and data not shown). While cell proliferation was normal in most tissues, there was evidence of decreased proliferation and increased apoptosis in the myocardium and the first branchial arch of *TKO* embryos ([Supplementary Fig. 5a--d](#SD1){ref-type="supplementary-material"}). These latter observations are consistent with heart defects found in *E2f3* singly-deleted adult mice[@R12].

To explore whether E2F1-3 might have cell cycle-related functions in tissues that arise later in embryonic and postnatal development, we exploited the highly organized cellular architecture of the small intestine. Maintenance of structural and functional integrity of the small intestine requires continuous epithelial regeneration[@R13]. Intestinal stem cells are housed at the base of crypts of Lieberkühn and give rise to transit-amplifying cells. As these cells migrate up from the base and into the finger-like extensions called villi, they exit the cell cycle and differentiate[@R13]. Western blot assays showed that *E2f1*, *E2f2* and both isoforms of *E2f3* (E2F3a and E2F3b) are expressed in the crypt and villus ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). We used *Ah-cre* mice[@R14] to ablate *E2f1-3* in the small intestine *in utero* or in adult mice (*Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^*, *TKO*). Induction of *Ah-cre* expression by intraperitoneal injection of β-napthoflavone (β-NF) led to the efficient deletion of *E2f3^LoxP^* in crypt stem cells and transit-amplifying cells by one day post-injection, and in the entire intestinal epithelium within 3--4 days (crypt and villus; [Supplementary Fig. 7a--c](#SD1){ref-type="supplementary-material"}). Loss of *E2f1-3* did not result in a compensatory increase of other E2F family members, except for a modest increase in *E2f8* ([Supplementary Fig. 7d](#SD1){ref-type="supplementary-material"}). Whether *E2f3^LoxP^* was deleted *in utero* at E15.5 or in the adult at 2 months of age, the architecture of *TKO* small intestines remained relatively intact and animals were asymptomatic for 90 days following β-NF administration ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Fig. 8a, 8b](#SD1){ref-type="supplementary-material"}). Cell-type specific marker analysis demonstrated that all differentiated epithelial cell-types were appropriately represented in *TKO* small intestines ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). Remarkably, cell proliferation was identical in *TKO* and *control* intestines ([Fig. 2c](#F2){ref-type="fig"}), however, we noted a marked increase in γ-H2AX and P-ATM^1981^ staining in *TKO* crypts and villi ([Fig. 2d, 2e](#F2){ref-type="fig"}, [Supplementary Fig. 10a](#SD1){ref-type="supplementary-material"}). A parallel analysis of retinal (*Chen et al*, accompanying manuscript) and lens (P.W. unpublished observations) progenitors also revealed increased γ-H2AX staining in *TKO* samples ([Supplementary Fig. 10b, 10c](#SD1){ref-type="supplementary-material"}). Together, these observations suggest that counter to current dogma, E2F1-3 are dispensable for the proliferation of embryonic stem cells and their mesodermal, endodermal, and ectodermal derivatives, and cells in at least some adult tissues.

Close examination of H&E-stained slides revealed increased numbers of pyknotic nuclei in *TKO* crypts (data not shown). TUNEL and cleaved caspase-3 assays confirmed the presence of apoptotic cells in crypts of *TKO* intestines ([Fig. 2f](#F2){ref-type="fig"}). We also observed increased p53 immunoreactivity in *TKO* crypts ([Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"}), which was reminiscent of previous work showing exquisite sensitivity of this cellular compartment to oncogene- and radiation-induced p53 responses[@R15]. While p53 was elevated in *TKO* crypts, we failed to detect any significant increase in the expression of p53-responsive genes and moreover, the conditional ablation of *p53* (*Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^;p53^LoxP^*^/^*^LoxP^*) did not suppress the apoptosis caused by *E2f1-3* deficiency ([Supplementary Fig. 11b, 11c](#SD1){ref-type="supplementary-material"}). Together, these surprising observations suggest that E2F1-3 are dispensable for cell division in the adult and that at least in the small intestine, they function in a p53-independent manner to maintain DNA integrity and cell survival.

To understand the underlying mechanism for these unexpected results, we isolated crypt and villus cell populations from *control* and *E2f1-3*-deficient (*TKO*) small intestines and analyzed global gene expression profiles. Sample preparation and processing of the Affymetrix oligo-arrays are described in the Methods section. We utilized an unbiased method similar to Gene Set Enrichment Analysis to identify genes that were differentially expressed[@R16]. Two variables contributed to the observed gene expression changes, cell compartment (crypt vs. villus) and genotype (*TKO* vs. *control*). The cell compartment analysis compared gene expression in crypts and villi of the same genotype ([Fig. 3a](#F3){ref-type="fig"}). For *control* small intestines, this revealed that among the \~45K genes queried, 1207 genes were upregulated and 2363 genes were downregulated as progenitor cells in the crypt migrated up into the villus and exited the cell cycle (\>1.5-fold, p\<0.0001; [Supplementary Fig. 12a](#SD1){ref-type="supplementary-material"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). As expected, the expression of most known E2F targets, as defined by previous gene expression[@R17], reporter and chromatin immunoprecipitation assays[@R18] ([Supplementary Fig. 12b](#SD1){ref-type="supplementary-material"}), was markedly higher in *control* crypts than in associated villi ([Fig. 3a](#F3){ref-type="fig"}, left panel), consistent with the proliferative status of crypts. For *TKO* small intestines, the expression of E2F targets in crypts was only marginally higher than in their associated villi ([Fig. 3a](#F3){ref-type="fig"}, right panel), suggesting that expression of these genes were either reduced in crypts, elevated in villi, or both.

The genotype analysis compared gene expression in *TKO* vs. *control* samples of the same cell compartment. This comparison revealed a modest but significant downregulation of E2F targets in progenitor cells of *TKO* crypts, which included many but not all known classic targets such as *Cdc6*, *Cyclin A2*, *Cyclin E2*, *Top2*, and *Hmgb2* ([Fig. 3b--c](#F3){ref-type="fig"}, left panels, [Supplementary Fig. 13a](#SD1){ref-type="supplementary-material"}). We suspect that continued proliferation of *TKO* progenitors in the small intestine when E2F targets are limiting likely contributes to replicative stress, DNA damage and the observed increase in γ-H2AX labeling in these cells. Whether these aberrant processes are linked to the death of *TKO* progenitor cells remains to be rigorously evaluated. The genotype comparison also revealed a remarkable upregulation of a large number of E2F targets in differentiated cells of the *TKO* villus ([Fig. 3b--c](#F3){ref-type="fig"}, right panels, [Supplementary Fig. 13a](#SD1){ref-type="supplementary-material"}). Western blot assays and IF staining showed that the accumulation of two of these E2F target gene products, Mcm3 and Pcna, was widespread throughout the *TKO* villus ([Fig. 3d](#F3){ref-type="fig"}, [Supplementary Fig. 13b](#SD1){ref-type="supplementary-material"}). Similarly, there was increased expression of E2F targets in differentiated *TKO* cells of the retina and lens ([Supplementary Fig. 13c](#SD1){ref-type="supplementary-material"}; PW unpublished observations), suggesting a general role for E2F1-3 in transcriptional repression in post-mitotic cells *in vivo*. Chromatin immunoprecipitation (ChIP) assays using villus-enriched lysates derived from *control* and *TKO* small intestines showed that E2F3 occupies E2F binding sites on classic E2F-target promoters ([Fig. 3e](#F3){ref-type="fig"}). Importantly, coimmunoprecipitation assays using intestinal epithelial cells derived from *E2f3*^−/−^, *E2f3a*^−/−^ and *E2f3b*^−/−^ villi showed that both E2F3a/b isoforms[@R19]--[@R21] participate in a complex with the Rb protein ([Fig. 3f](#F3){ref-type="fig"}). Consistent with this, Rb was found to be hypophosphorylated in the villus ([Supplementary Fig. 14a](#SD1){ref-type="supplementary-material"}). Together, these data suggest that E2F1-3 act as transcription activators in dividing progenitors, and as repressors (in complex with Rb) in differentiating cells of the small intestine.

On the surface, the observation that E2F1-3 repress E2F targets and are dispensable for cell proliferation contradict previous findings from the analysis of *Rb*/*E2f* double knockout animals[@R1], [@R2], [@R8]. Therefore, to thoroughly explore the mechanistic relationship between Rb and E2F1-3, we used the small intestine as an *in vivo* system where results could be uniformly compared across different genetic configurations. The *Ah-*cre mediated inactivation of *Rb in utero* or in adult mice resulted in increased proliferation of cells in the villus compartment but not in the crypt ([Fig. 4a, 4b](#F4){ref-type="fig"}, [Supplementary Fig. 14b--e](#SD1){ref-type="supplementary-material"}), indicating that *Rb-*deleted transit-amplifying cells failed to appropriately exit the cell cycle. There was, however, no concomitant increase in apoptosis or defect in cell differentiation ([Supplementary Fig. 15a, 15b](#SD1){ref-type="supplementary-material"}), and as a result, *Rb*-deficient villi appeared uniformly hyperplastic. The combined ablation of the three *E2fs* completely suppressed the unscheduled proliferation and hyperplasia caused by *Rb* deficiency (*QKO*; [Fig. 4a, 4b](#F4){ref-type="fig"}, [Supplementary Fig. 16a](#SD1){ref-type="supplementary-material"}). Importantly, the basal levels of proliferation in *QKO* crypts were indistinguishable from control or *TKO* samples ([Supplementary Fig. 16b](#SD1){ref-type="supplementary-material"}), consistent with the rather normal development of *E2f1-3* deficient small intestines containing an intact *Rb* gene.

The selective requirement for *E2f1-3* in the proliferation of *Rb*-deficient cells provided an opportunity to dissect possible cancer-specific mechanisms of E2F in cell cycle control. We therefore compared global gene expression programs in *control*, *RbKO*, *TKO* and *QKO* intestinal epithelia. Several important insights came from this analysis. First, there were expansive gene expression differences between *control* and *RbKO* villi (1290 upregulated and 487 downregulated genes; [Fig. 4c](#F4){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}), but relatively minor differences in their associated crypts ([Supplementary Fig. 17a, 17b](#SD1){ref-type="supplementary-material"}). Gene Ontology algorithms[@R22] identified a bias for differentially expressed genes involved in the regulation of transcription, DNA metabolic processes and cell cycle ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). IF and quantitative RT-PCR assays confirmed the dramatic accumulation of most E2F-target genes in *RbKO* villi ([Supplementary Fig. 17c--d](#SD1){ref-type="supplementary-material"}). From these data we conclude that *Rb* is critical for the repression of E2F targets at a time when progenitor cells commit to exit the cell cycle and terminally differentiate. Second, hierarchical clustering of all data sets showed that *TKO* and *QKO* tissues clustered together in a separate group from *control* and *RbKO* tissues ([Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}), suggesting that some functions coordinated by E2F1-3 may be Rb-independent. Finally and most importantly, the expression levels of E2F targets in *TKO* and *QKO* villi were equivalent, and while higher than in *control* villi, they were substantially lower than in *RbKO* villi ([Fig. 4c](#F4){ref-type="fig"}). Quantitative RT PCR assays confirmed the relative expression of E2F targets to be: *control* \< *TKO* = *QKO* ≪ *RbKO* ([Fig. 4d](#F4){ref-type="fig"}). From these data, we conclude that the supra-elevated expression of E2F targets observed in *RbKO* villi is due to both 'derepression' (lacking intact Rb/E2F1-3 repressor complexes) and E2F1-3 mediated 'hyper-activation'. In the absence of E2F1-3 mediated hyper-activation, cells in *QKO* villi fail to hyper-activate and thus do not accumulate sufficient levels of E2F targets to undergo 'ectopic' cell proliferation (this threshold level of expression is illustrated as a red dotted line in [Fig. 4d](#F4){ref-type="fig"}).

We provide overwhelming evidence showing that normal cell proliferation in mice can be maintained in the absence of activator E2Fs. We conclude that E2F1-3, like G~1~ Cdk's[@R23]--[@R25], are not as critical for normal cell proliferation in mammals as original studies implied[@R3], [@R4], [@R26]--[@R29]. However, not all is well in the absence of E2F1-3, since *TKO* dividing progenitors in the small intestine undergo apoptosis. A prosurvival role for E2F1-3 was also evident in retinal progenitor cells of the mouse (*Chen et al*., accompanying paper), however, in the retina cell death was p53 dependent whereas in the small intestine it was p53 independent. Thus, the sensitivity of cells to p53 activation varies considerably across tissue types.

The findings presented here also expose dual functions for E2F1-3 in transcription activation and repression *in vivo*. In dividing progenitor cells, when Rb is inactive (hyperphosphorylated), free E2F1-3 are employed to optimally activate the expression of target genes. The inability to do so in *E2f1-3* deficient tissues still permits cells to replicate their DNA and divide, but at the cost of increased DNA damage and cell death. As cells commit to a terminally differentiated fate, P-Rb is dephosphorylated and forms a physical complex with E2F1-3 proteins. We propose that this is not to just sequester E2F activators but rather, to form the first repressive complex that is necessary to downregulate E2F targets and usher transit-amplifying cells out of the cell cycle. Once cells exit the cell cycle, other professional repressor complexes accumulate, including p130/E2F4 and p107/E2F4, to more permanently enforce the repression of E2F targets. Given that inactivation of *Rb*, but not *p*107 or *p130*[@R30], induces ectopic cell divisions in the small intestine, we suggest that Rb has a unique role in transit-amplifying cells that is dependent on its ability to associate with E2F1-3. Maintenance of quiescence in terminally differentiated cells of the villus, however, is a function that is shared among all members of the Rb family[@R30]. In summary, this work challenges the current paradigm of cell cycle control and provides, for the first time, a unified molecular view of how the dual functions of E2F1-3 in transcriptional activation and repression are employed *in vivo* to control normal versus *Rb*-mutant or cancer cell cycles.

METHODS SUMMARY {#S1}
===============

Mice (*E2f1*^−/−^, *E2f2*^−/−^, *E2f3^f^*^/^*^f^*, *Ah-cre* and *Rb^f^*^/^*^f^*) used for the studies were in mixed background (129SvEv, C57BL/6NTac and FVB/NTac). β-napthoflavone (sigma; N3633-5G) was administered into 2 month old *Ah-cre* mice three times within 24 hours as described previously[@R14] and mice were harvested 7 or 90 days later. β-napthoflavone was also injected into pregnant female mice at 15.5 days postcoitum for analysis of embryos at E18.5. Villus and crypt fractions were isolated as previously described[@R8]. Three independent samples from each genetic group were used for gene expression analysis by Affymetrix microarray. Analysis of gene expression data were performed using BRB-array tools developed by Dr. Richard Simon and Amy Peng Lam of the National Cancer Institute. Gene Ontologies were predicted by DAVID (Database for Annotation, Visualization and Integrated Discovery) Bioinformatics Resources at the National Institute of Allergy and Infectious diseases, NIH. X-gal staining, real-time RT-PCR, BrdU, ChIP and TUNEL assays were performed as previously described[@R8], [@R19]. Primers for ChIP, real-time RT-PCR and genotyping are listed in [Supplementary Fig. 19a-b](#SD1){ref-type="supplementary-material"}. Antibodies used for Western blot or immunohistochemical staining are listed in [Supplementary Fig. 19c](#SD1){ref-type="supplementary-material"}.

Supplementary Material {#S2}
======================

###### 

**Supplementary Figure 1**. Deletion of *E2f1-3* does not impair ES cell growth or differentiation. **a.** PCR genotyping of multiple ES cell clones after electroporation with a cre-expressing plasmid driven by the elongation factor-1 promoter (EF1-cre). **b.** Expression levels of *nanog*, *oct4*, *eomes and cdx2* were measured by quantitative RT-PCR in trophoblast stem (TS) cells and ES cell clones. Consistent with the pluripotency of ES cells derived from *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/−^ embryos, these cells expressed high levels of *oct4* and *nanog* but low levels of *cdx2* and *eomes* (TS cell markers). ES cells were derived from blastocysts at E3.5 from crosses between *E2f1*^+/−^; *E2f2*^−/−^; *E2f3*^+/−^ and *E2f1*^+/−^; *E2f2*^−/−^; *E2f3^LoxP^*^/^*^LoxP^* mice. Colonies that grew from disaggregated blastocysts with ES cell-like morphology were subcultured for expansion and were genotyped by PCR for *E2f1*, *E2f2*, and *E2f3. E2f1*^+/−^; *E2f2*^−/−^; *E2f3^LoxP^*^/−^ clones derived from two different embryos were expanded and electroporated with EF1-Cre. Cells were plated at low density after electroporation and colonies were collected for genotyping and further culture. Approximately 55% to 70% of the resulting clones underwent recombination of the conditional *E2f3* allele without any form of selection. Finally, ES cells were checked for expression of ES cell-specific and trophoblast stem (TS) cell-specific markers to verify their identities.

**Supplementary Figure 2**. E2F3 expression and promoter-binding activity in ES cells. **a.** Real-time RT-PCR analysis of *E2f1*, *E2f2*, *E2f3a*, and *E2f3b* expression in *wild type* MEFs and ES cells (TC-1 line). **b.** The TC-1 *wild type* ES cell line expresses equivalent levels of E2F3 protein as detected by Western blots probed with anti-E2F3. *E2f1-3* triply-deleted (TKO) ES cells are used as a negative control. **c.** Chromatin immunoprecipitation was done with anti-E2F3 antibodies, using control (−) or cre-treated (+) *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* MEFs (left panel) as well as *DKO* and *TKO* ES cells (right panel).

**Supplementary Figure 3**. Gene expression and E2F4/p130 mediated repression in *DKO* and *TKO* ES cells. **a.** Real-time RT-PCR analysis of p53 target gene expression in control (−) or cre-treated (+) *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* MEFs (left panel) as well as *DKO* and *TKO* ES cells (right panel). The binding of E2F4 (**b**) and p130 (**c**) to E2F target promoters in control (−) or cre-treated (+) *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* MEFs (left panel) as well as *DKO* and *TKO* ES cells (right panel) was detected by chromatin immunoprecipitation with anti-E2F4 and anti-p130 antibodies, respectively.

**Supplementary Figure 4**. *E2f1*, *E2f2*, and *E2f3* are dispensable for teratoma formation. **a.** Pluripotency of ES cell lines was measured by scoring the number of teratomas containing defined cell lineages (neural, muscle, epithelial, skin and inflammatory) from a total number of teratomas that developed in mice injected with one wild type ES cell line (TC-1), two *DKO* ES cell lines, and two *TKO* ES cell lines. **b.** Growth rates of teratomas in (a) were calculated as the number of days required for teratomas to reach a volume of 200 mm^3^.

**Supplementary Figure 5.** Cell proliferation and apoptosis in *TKO* embryos. Ki67 (**a**) and TUNEL (**c**) staining of various organs from E9.5 *E2f1*^+/+^;*E2f2*^−/−^;*E2f3*^+/+^ (*SKO*), *E2f1*^−/−^;*E2f2*^−/−^;*E2f3*^+/+^ (*DKO*) and *E2f1*^−/−^;*E2f2*^−/−^;*E2f3*^−/−^ (*TKO*) embryos. Quantification of Ki-67-positive (**b**) and TUNEL-positive (**d**) cells from a minimum of three embryos of each genotype (*SKO*, *DKO* and *TKO*); at least three sections for each embryo were analyzed. Error bars represent standard deviation.

**Supplementary Figure 6.** Detection of E2F1, E2F2 and E2F3 proteins in the small intestine. Western blots of protein lysates derived from *wild type* crypts and villi were probed with antibodies specific for E2F1, E2F2, and E2F3. Villi lysates derived from *Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* small intestines (*TKO*) were used as a negative control; note that a small amount of spill-over occurred from the adjacent lane. Tubulin was used as a loading control.

**Supplementary Figure 7.** Expression of *Ah-cre* and inactivation of *E2f3^LoxP^*^/^*^LoxP^* in the small intestine. **a.** *In situ* X-Gal staining was used to examine the expression of *cre-*recombinase in the small intestines of *Rosa26^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;Rosa26^LoxP^*^/^*^LoxP^* (*Ah-cre*) mice after one, two and three days following β-napthoflavone (β-NF) injection. Deletion of *E2f3^LoxP^* was measured by Southern blot (**b**) and PCR (**c**) of DNA isolated from small intestines with the indicated genotypes. **d.** Real-time RT-PCR was used to measure *E2f4-8* expression in villi from *control* and *TKO* small intestines.

**Supplementary Figure 8.** Normal architecture of *E2f1-3* deficient small intestines. **a.** H&E stained sections of small intestines from *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*) pups that were harvested 3 and 24 days following β-NF administration into pregnant females (at 15.5 d.p.c.). **b.** H&E stained sections of small intestines from *control* and *Ah-cre* mice harvested 7 and 90 days following the administration of β-NF into 2 month-old mice.

**Supplementary Figure 9.** Normal cell differentiation in *E2f1-3* deficient small intestines. Antibodies specific against cholecystokinin (CCK, red), somatostatin (red), serotonin (red) and lysozyme (red) were used for identifying various differentiated endocrine cells in *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*) small intestines. DAPI (blue) is used for staining nuclei. Arrows point to positively-stained cells.

**Supplementary Figure 10.** Increased γ-H2AX staining in *E2f1-3* deficient small intestines **a.** Immunohistochemical staining of γ-H2AX (red) and P-ATM^1981^ (red) in *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*) intestinal crypts. DAPI (blue) was used for staining nuclei. The arrows indicate positively-stained cells. **b.** Immunohistochemical staining of γ-H2AX (red) in wild type (*control*) and cre-treated *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*E2f1-3 TKO*) retinas at various developmental stages indicated (E14, P0 and P18). **c**. Quantification of the γ-H2AX positive cells stained in (b).

**Supplementary Figure 11.** Loss of E2F1-3 in the small intestine causes cell death in crypts. **a.** Small intestine sections from *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre* (*TKO*)) mice injected with β-NF and harvested 7 days later were stained with antibodies for p53. **b.** TUNEL assays were performed on small intestine sections from *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^*;*p53^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^*;*p53^LoxP^*^/^*^LoxP^* (*Ah-cre* (*QKO*)) mice treated as in (a). **c.** Quantification of TUNEL-positive cells from (b). Three mice were analyzed for each genetic group. Error bars represent standard deviation.

**Supplementary Figure 12.** Heirarchical clustering analysis of differentially expressed genes (\>1.5-fold and p\<0.0001) in *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*) villi and crypts is presented as a heat map (**a**). Samples from three animals of each genetic group were used for the analysis. **b.** List of E2F target genes as defined by previous gene expression, reporter and ChIP assays[@R17], [@R18].

**Supplementary Figure 13.** Expression of E2F-responsive genes is upregulated in *E2f1-3* deficient small intestines and retinas. **a**. Quantitative real-time PCR was used to examine the relative expression of selected E2F-target genes in *control* and *Ah-cre* crypts (left panels) and villi (right panels) using specific primers (Supplementary Fig. 20). **b.** Examination of Mcm3 and Pcna protein levels in *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*) villi by Western blot. **c.** Relative quantitative real-time PCR of a panel of genes in wild type and cre-treated P14 *E2f1*^−/−^;*E2f2*^−/−^;*E2f3^LoxP^*^/^*^LoxP^* (*TKO*) retinas. Expression in *TKO* samples was relative to control (wild type) samples.

**Supplementary Figure 14.** Loss of *Rb* in differentiating intestinal crypt cells (crypt) results in ectopic proliferation in villi. **a.** Cell extracts isolated from control crypts and villi were used to detect Rb protein in Western blots. RbKO, *Rb* knockout crypt; Rb-P, hyperphosphorylated Rb; Rb, hyporphosphorylated Rb. **b.** PCR based assay used to examine deletion of the *Rb^LoxP^* allele from genomic DNA purified from small intestines of *Rb*^+/+^, *Rb^LoxP^*^/^*^LoxP^* (−), *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (+) mice after 7 days of β-napthoflavone (β-NF) administration. **c.** Small intestines from β-NF-injected 2 month-old *Rb^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (*RbKO*) mice were harvested 7 or 90 days later, sectioned and stained with H&E. **d**. BrdU analysis was performed in *control* and *RbKO* intestines harvested at embryonic day 18.5 (E18.5) and at 2 months of age (P60). For the embryonic analysis of the small intestine (E18.5), β-NF was injected into pregnant females at 15.5 d.p.c. Other details of β-NF injection and tissue harvesting are provided in the Methods section. **e**. Quantification of BrdU incorporation in villi and crypts of animals with the indicated genotypes and ages. n=3, 3 different animals with the indicated genotypes were analyzed. Error bars indicate standard deviation.

**Supplementary Figure 15.** Normal differentiation of *Rb-*deficient small intestines. **a.** Small intestine sections from *Rb^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (*RbKO*) mice, which were injected with β-NF and harvested 7 days after, were used for TUNEL staining. **b.** Analysis of cell differentiation in *control* and *RbKO* small intestines. Alcian blue, goblet cells were identified by Alcian blue staining; other antibody-based markers for cholecystokinin (CCK, red), serotonin (red), somatostatin (red), lysozyme (red) and fatty acid binding protein (FABP, green) were used to identify endocrine cells, paneth cells, and absorptive cells, respectively. DAPI (blue) was used for staining nuclei. Arrows indicate positive-stained differentiated cells.

**Supplementary Figure 16.** Normal cell proliferation in *Rb*-deficient crypts of the small intestine. **a.** Sections of small intestines from *Rb^LoxP^*^/^*^LoxP^* (*control*), *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (*RbKO*) and *Ah-cre;Rb^LoxP^*^/^*^LoxP^;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*QKO*) mice that were harvested 7 days post-β-NF-injection were stained with H&E. **b.** BrdU analysis was performed in *control*, *RbKO* and *QKO* small intestines from mice treated as in (a). Quantification of BrdU incorporation in crypts of three different animals with the indicated genotypes. Error bars indicate standard deviation.

**Supplementary Figure 17.** Global gene expression analysis in the *Rb*-deficient small intestine. **a.** Heatmap representation of heirarchical clustering analysis of differentially expressed genes in crypts and villi of *Rb^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (*RbKO*) mice (p\<0.0001). Three independent samples from each genetic group and tissue (crypt/villus) were analyzed. **b.** Scatter plots comparing the expression of known E2F-target genes in *control* and *RbKO* crypt and villus. **c**. Expression of E2F-target genes in *control* and *RbKO* villi was examined by Real-time RT-PCR. The two bars for each set represents two independent samples of that genotype. Error bars indicate standard deviation from triplicate samples. **d**. Immunohistochemical staining of Mcm3 (green) and Pcna (red) in *control*, *RbKO* and *QKO* villi. DAPI (blue) was used for staining nuclei. Yellow dotted line outlines the luminal side of the villus; white dotted line outlines the outer side of the villus. Note that staining of blood cells in lumens of villi is non-specific.

**Supplementary Figure 18.** Hierarchical clustering analysis of differentially expressed genes in *control*, *RbKO (RKO*), *TKO*, *QKO* villi (p\<0.0001). Note that wild type (CON) and *RKO* samples segregate from *TKO* and *QKO* villi samples; a similar separation of genetic groups was achieved when the associated crypts were analyzed in the same manner.

**Supplementary Figure 19.** List of Primers used for genotyping (**a**) and ChIP assays (**b**). **c**. List of antibodies used in this study.

**Supplementary Figure 20.** List of Primers used for real-time RT-PCR analysis of gene expression.
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![Cell proliferation in the absence of *E2f1-3*\
**a** Expression of E2F-regulated genes was measured by real-time RT-PCR in proliferating ES and MEFs cells with the indicated genotypes (primer information is provided in [Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}). **b.** Growth curves of two sets of *DKO* and *TKO* ES cell clones (A and B) and *DKO* and *TKO* MEFs. **c.** *DKO* and *TKO* ES cells were injected underneath the skin of athymic nude mice and teratomas were harvested, sectioned and stained with H&E. Representative tissues of *DKO* and *TKO* teratomas include muscle (mesoderm), respiratory epithelium (endoderm), skin and neural cells (ectoderm). **d.** Embryos derived from intercrosses between *E2f1*^+/−^;*E2f2*^−/−^;*E2f3*^+/−^ mice were collected at various timepoints during pregnancies. **e.** Representative E9.5 embryos were photographed immediately upon collection; *E2f2*^−/−^ (*SKO*), *E2f2*^−/−^*;E2f3*^−/−^ (*DKO*), and *E2f1*^−/−^*E2f2*^−/−^*E2f3*^−/−^ (*TKO*) embryos.](nihms159831f1){#F1}

![Apoptosis of crypt intestinal cells in the absence of E2f1, E2f2, and E2f3\
**a** H&E stained sections from E2f1^−/−^;E2f2^−/−^;E2f3^LoxP/LoxP^ (control) and Ah-cre;E2f1^−/−^;E2f2^−/−^;E2f3^LoxP/LoxP^ (Ah-cre) intestines after 90 days of β-NF administration. **b**. Analysis of cell differentiation in control and Ah-cre small intestines. Goblet cells were identified by Alcian blue staining (arrows point to positive-stained goblet cells); absorptive cells were identified by anti-Fatty acid binding protein (FABP, green) antibodies; DAPI (blue) was used for staining nuclei. **c.** BrdU (brown) and phosphorylated histone H3 (P-H3, red) immunohistochemical staining was performed on small intestine sections from β-NF injected control and Ah-cre mice. Quantification of BrdU- and phosphorylated histone H3-positive cells in crypts and villi. n=3, 3 different animals with the indicated genotypes were analyzed (bottom panels); error bars indicate standard deviation. **d**. Immunohistochemical staining for γ-H2AX, P-ATM^1981^ in *control* and *Ah-cre* intestinal crypts and villi. The orange dotted line outlines the luminal side of the villus; the white dotted line outlines the outer side of the villus. DAPI (blue) was used for staining nuclei. **e**. Examination of γ-H2AX and P-ATM^1981^ in cell extracts from *control* and *Ah-cre* intestinal crypts and villi by Western blot assays. **f**. Sections of small intestines from β-NF injected *control* and *Ah-cre* mice were processed for TUNEL (brown) and cleaved caspase-3 (red) assays. DAPI (blue) or hematoxylin was used for staining nuclei. Quantification of TUNEL and cleaved caspase-3 positive cells in crypts and villi (bottom panels). n=3, 3 different animals with the indicated genotypes were analyzed; error bars indicate standard deviation.](nihms159831f2){#F2}

![Repression of E2F-target genes in *E2f1-3* deficient villi\
**a** Scatter plots comparing expression of known E2F-target genes (see [Supplementary Fig. 16b](#SD1){ref-type="supplementary-material"}) between cell compartments (crypt and villus); *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*control*) and *Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*Ah-cre*). Genes with \>1.5-fold increase in expression are depicted as red dots. **b.** Scatter plots comparing expression of known E2F-target genes between genotypes (*control* and *Ah-cre* samples); n=3 for each of the four samples. Red dots indicate genes whose expression increased \>1.5-fold and blue dots indicate genes that decreased \>1.5-fold. **c.** Quantitative real-time PCR was performed to compare the relative expression of selected E2F-target genes in *control* and *Ah-cre* crypts (left panels) and villi (right panels) using specific primers ([Supplementary Fig. 20](#SD1){ref-type="supplementary-material"}). **d**. Immunohistochemical staining of Mcm3 (green) and Pcna (red) in *control* and *Ah-cre* villi. DAPI (blue) was used for staining nuclei. Yellow dotted line outlines the luminal side of the villus; white dotted line outlines the outer side of the villus. Note that staining of blood cells in lumens of villi is non-specific. **e**. Chromatin immunoprecipitation (ChIP) assays using IgG or anti-E2F3 (α-3) antibodies with lysates from *wild-type* villi (Antibody control; top panels). ChIP assays using anti-E2F3 (α-3) antibodies with lysates from *wild type* (*con*) and *Ah-cre* (*TKO*) villi (Genotype control: bottom panels). Primers flanking known E2F-binding elements were used to detect the indicated gene promoters ([Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}). **f.** Co-immunoprecipitation assays of cell extracts prepared from *control* villi and crypts. Imunoprecipitations (IP) used anti-E2F3 antibody or IgG. Anti-Rb antibody was used to probe Western blot (WB; left panel). The specificity of the anti-E2F3 antibody used in the left panel was evaluated in intestinal lysates derived from *Ah-cre* (*3*^−/−^), *E2f3a*^−/−^ (*3a*^−/−^), *E2f3b*^−/−^ (*3b*^−/−^) and *E2f3*^+/+^ mice. Anti-Rb antibody was used to probe Western blot (WB; right panel).](nihms159831f3){#F3}

![E2F1-3 contribute to the ectopic cell proliferation caused by *Rb*-deficiency\
**a** BrdU analysis was performed in *E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*control*), *Ah-cre;Rb^LoxP^*^/^*^LoxP^* (*RbKO*) and *Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^*;*Rb^LoxP^*^/^*^LoxP^* (*QKO*) small intestines. **b.** Quantification of BrdU incorporation. n=3, 3 different animals with the indicated genotypes were analyzed; error bars indicate standard deviation. **c.** Scatter plot analysis comparing differentially expressed E2F target genes in *control, RbKO*, *Ah-cre;E2f1*^−/−^*;E2f2*^−/−^*;E2f3^LoxP^*^/^*^LoxP^* (*TKO*) and *QKO* villi; n=3 for each of the eight samples. Red dots indicate genes whose expression increased \>1.5-fold and blue dots indicate gene that decreased \>1.5-fold. **d.** Quantitative RT-PCR analysis of selected E2F-target genes in *control (con)*, *RbKO*, *TKO*, and *QKO* villi. The normal basal level of E2F target expression is illustrated as a grey dotted line and the threshold level of E2F target expression required for ectopic proliferation is illustrated as a red dotted line.](nihms159831f4){#F4}
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